… Dasatinib resulted active against all the imatinib resistant Bcr-Abl point mutations, except
for the T315I one (substitution of the amino acid threonine 315 with isoleucine) [16]. This …

… in imatinib-resistant patients: 96.84 % for OS, 93.73 % for PFS here, compared to 82 % for
OS and 66 % for PFS for dasatinib second-line [9]; and 70 % for and 33 % for PFS for nilotinib …

… A cytokine array analysis was performed on K562, K562 imatinib-resistant cells (K562/IR),
and … downregulating BCR-ABL and c-Myc expression after SB225002 treatment induced cell …

… -generation BCR::ABL1 tyrosine kinase inhibitors (TKIs) in Philadelphia chromosome (Ph)-positive
chronic myeloid … on treatment options in frontline and subsequent-line CML therapy, …

… second-generation tyrosine kinase inhibitors (TKIs) used for the treatment of chronic myeloid
… They invariably paired one of the most frequent imatinib-resistant mutation hotspots with …

… This led to the development of second generation TKIs. … in the treatment of imatinib-resistant
CML. The advantage of this … portion of BCR-ABL, but rather works as an allosteric inhibitor of …

… tyrosine kinase inhibitor imatinib as the first-line treatment in chronic myeloid leukemia (CML…
BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors …

… a critical role in CML by amplifying BCR-ABL signaling [112]. … resistant to TKIs and
Imatinib-resistant cell lines show higher … inhibition of autophagy using second generation …

… by imatinib and second generation BCR-ABL inhibitor. CML with … but also imatinib -resistant
cells with BCR-ABL mutation, which … the imatinib -resistant induced by inhibitors of BCR-ABL …

… treated using tyrosine kinase inhibitors (TKIs) such as imatinib, which prevent phosphorylation
of downstream targets by blockade of the BCR-ABL kinase… Further, imatinib-resistant CML …